Literature DB >> 14593704

The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation.

Tansy C Hammarton1, Jeremy C Mottram, Christian Doerig.   

Abstract

There is an urgent need to develop new drugs against eukaryotic parasitic protozoa such as Plasmodium, Trypanosoma and Leishmania, which cause the diseases malaria, trypanosomiasis and the leishmaniases respectively. The biology of these organisms has many unusual facets that might be exploited for drug design, and the recent availability of parasite genome sequence data has facilitated the search for novel drug targets. Here we review current understanding of the cell cycle in these parasites and show that important structural and functional differences exist between parasite and mammalian cell cycle control machineries and signal transduction pathways, which might be utilised for rational drug design. Potential targets include protein kinases from the cyclin-dependent kinase, cAMP-dependent kinase and mitogen activated protein kinase families.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593704

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  34 in total

1.  Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3.

Authors:  Kayode K Ojo; Tracy L Arakaki; Alberto J Napuli; Krishna K Inampudi; Katelyn R Keyloun; Li Zhang; Wim G J Hol; Christophe L M J Verlinde; Ethan A Merritt; Wesley C Van Voorhis
Journal:  Mol Biochem Parasitol       Date:  2010-12-30       Impact factor: 1.759

2.  Symmetrical choline-derived dications display strong anti-kinetoplastid activity.

Authors:  Hasan M S Ibrahim; Mohammed I Al-Salabi; Nasser El Sabbagh; Neils B Quashie; Abdulsalam A M Alkhaldi; Roger Escale; Terry K Smith; Henri J Vial; Harry P de Koning
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

3.  Pairwise knockdowns of cdc2-related kinases (CRKs) in Trypanosoma brucei identified the CRKs for G1/S and G2/M transitions and demonstrated distinctive cytokinetic regulations between two developmental stages of the organism.

Authors:  Xiaoming Tu; Ching C Wang
Journal:  Eukaryot Cell       Date:  2005-04

Review 4.  Kinetoplastids: related protozoan pathogens, different diseases.

Authors:  Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  Trypanosoma brucei MOB1 is required for accurate and efficient cytokinesis but not for exit from mitosis.

Authors:  Tansy C Hammarton; Simon G Lillico; Sue C Welburn; Jeremy C Mottram
Journal:  Mol Microbiol       Date:  2005-04       Impact factor: 3.501

Review 6.  Protein kinases as drug targets in trypanosomes and Leishmania.

Authors:  Christina Naula; Marilyn Parsons; Jeremy C Mottram
Journal:  Biochim Biophys Acta       Date:  2005-09-08

7.  A type II ribonuclease H from Leishmania mitochondria: an enzyme essential for the growth of the parasite.

Authors:  Smita Misra; Jabbar Bennett; Yeshitila N Friew; Junaid Abdulghani; Charletha V Irvin-Wilson; Manish K Tripathi; Shauntae Williams; Minu Chaudhuri; Gautam Chaudhuri
Journal:  Mol Biochem Parasitol       Date:  2005-10       Impact factor: 1.759

8.  Coupling of posterior cytoskeletal morphogenesis to the G1/S transition in the Trypanosoma brucei cell cycle.

Authors:  Xiaoming Tu; Ching C Wang
Journal:  Mol Biol Cell       Date:  2004-11-03       Impact factor: 4.138

9.  New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.

Authors:  Ranjan Behera; Sarah M Thomas; Kojo Mensa-Wilmot
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

Review 10.  Molecular machinery of signal transduction and cell cycle regulation in Plasmodium.

Authors:  Fernanda C Koyama; Debopam Chakrabarti; Célia R S Garcia
Journal:  Mol Biochem Parasitol       Date:  2009-01-21       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.